Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.0252W HIGH $42.80
Volume
61.88 K
Value Traded
187.86 K
Short % Float
0.62%
-6.77%Week
-23.08%1 Month
-41.43%3 Month
+112.27%6 Month
-98.75%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
15.83 M
EPS (TTM)
-15.90
P/E Ratio
-
Ent. Value
8.83 M
Total Shares
1.95 M
Float Shares
1.74 M
Insiders
0.40%
Institutions
8.57%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
AKTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Akari Therapeutics Plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Akari Therapeutics Plc
635Total events
11Upcoming
88Tier-1 (high impact)
2014 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Composition Patent FiledIP / Competition
PCT/US2026/45955 filed covering PH1 splicing-modulating ADC payload
●R&D DayPresentation
Akari pre-recorded fireside chat at H.C. Wainwright 28th Annual Global Investment Conference
●Oral PresentationPresentation
Akari CEO panel on novel ADC payloads at Oncology & Immunology Innovation Partnering & Licensing Summit
▲Preclinical PoCAKTX-101Preclinical
AKTX-101 demonstrated robust anti-tumor activity in urothelial cancer preclinical models
urothelial cancersource ↗
●IND Enabling CompleteAKTX-101Preclinical
Akari advancing IND-enabling activities for AKTX-101
urothelial cancersource ↗
▲Partnership / LicenseCorporate
Research collaboration with Whitehawk Therapeutics on dual-payload ADCs
▲Patent GrantedIP / Competition
Newly issued international patents for PH1 payload technology
▲Partnership / LicenseCorporate
Strategic research collaboration with WhiteHawk Therapeutics announced
▲Partnership / LicenseCorporate
Strategic research collaboration with Whitehawk Therapeutics announced
●IND Enabling CompleteAKTX-101Preclinical
IND-enabling studies initiated for AKTX-101
cancer (Trop2-expressing tumors)source ↗
▲Partnership / LicenseCorporate
Strategic research collaboration with Whitehawk Therapeutics to evaluate PH1 payload in combination with TOP1i payload
●Preclinical PoCPreclinical
Preclinical studies evaluating PH1 payload in combination with Whitehawk's TOP1i ADC platform
cancersource ↗
◆Corporate ApprovalCorporate
Annual General Meeting scheduled for June 30, 2026 to approve warrant issuance
▲Oral PresentationPresentation
ASCO 2026 abstract presentation on preclinical data for PH1 ADC payload with KRAS inhibitor in pancreatic cancer models
KRAS-driven cancerssource ↗
▲AbstractAKTX-101Presentation
ASCO abstract acceptance for AKTX-101 preclinical data
KRAS-driven cancerssource ↗
●Oral PresentationAKTX-101Presentation
Virtual Investor 'What This Means' interview discussing ASCO abstract
KRAS-driven cancerssource ↗
◆AbstractAKTX-101Presentation
ASCO abstract acceptance for AKTX-101 combination synergy with K-Ras inhibitor in KRAS-mutated pancreatic cancers
KRAS-mutated pancreatic cancerssource ↗
▲Preclinical PoCAKTX-101Preclinical
Preclinical data demonstrating synergistic activity of AKTX-101 with adagrasib in KRAS-mutated pancreatic cancer models
KRAS-mutated pancreatic cancersource ↗
▲Patent GrantedIP / Competition
European patent granted for Thailanstatin analogs (EP 3684773B1)
●IND Enabling CompleteAKTX-101Preclinical
IND-enabling studies ongoing for AKTX-101
cancer (TROP2-expressing tumors)source ↗
▲Patent GrantedIP / Competition
Australian patent acceptance for Thailanstatin analogs covering PH1 payload
▲Poster PresentationAKTX-101Presentation
Positive preclinical data for AKTX-101 presented at AACR 2026
TROP2-expressing cancers (bladder, lung, breast)source ↗
◆Poster PresentationPresentation
Abstract accepted for poster presentation at AACR 2026 on rationale for Trop2 ADC development
solid tumors of the bladder, lung, and breastsource ↗
▲Partnership / LicenseCorporate
Strategic partnership with WuXi XDC to advance PH1 payload development
▼Equity OfferingCorporate
Private placement and warrant exercises raising approximately $8.6 million
▼Reverse Stock SplitCorporate
ADS ratio change from 1:2000 to 1:80000 effective March 31, 2026
●IND Enabling CompleteAKTX-101Preclinical
IND enabling studies initiated for AKTX-101
Trop2-expressing cancerssource ↗
▲IND Enabling CompleteAKTX-101Preclinical
Initiation of IND-enabling activities through manufacturing partnership with WuXi XDC
Trop2-expressing tumorssource ↗
▲Pipeline PrioritizationAKTX-102Corporate
Pipeline expansion with introduction of AKTX-102 targeting CEACAM5
CEACAM5-expressing tumorssource ↗
●Composition Patent FiledIP / Competition
Multiple provisional patent filings covering PH1 payload, immune activation mechanisms, antibody design, and combination strategies
◆Oral PresentationPresentation
Akari Therapeutics to present at 2026 Biocom Global Partnering & Investor Conference
▲Development Candidate NominationAKTX-102Preclinical
Introduction of AKTX-102, second ADC pipeline candidate targeting CEACAM5
CEACAM5-expressing solid tumorssource ↗
◆Oral PresentationPresentation
Akari Therapeutics to present at Corporate Connect Webinar Series hosted by Webull Financial
●Composition Patent FiledAKTX-102IP / Competition
Filed U.S. provisional patent application No. 63/958,508 covering AKTX-102
CEACAM5 expressing solid tumorssource ↗
▲First Patient DosedAKTX-101Trial
First-in-human trial initiation for AKTX-101
Trop2-expressing cancerssource ↗
▲Oral PresentationPresentation
Preclinical data presented at ASCO 2026
KRAS-mutated pancreatic cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How AKTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-06-30 | nomacopan | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D22 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 89%
Micro Cap(rank 586 of 658)
Percentile Rank
Akari Therapeutics Plc faces pipeline headwinds (22/100), with $307M risk-adjusted pipeline value, led by Coversin in Paroxysmal Nocturnal Hemoglobinuria (PNH) (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Coversin Small moleculeCompletedNCT03427060 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | COMPLETED | 1 | Feb 3, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every AKTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Trastuzumab-PH1 | 2025-11-10 | In preclinical studies, the combination of Trastuzumab-PH1 and anti-PD1 therapy resulted in a complete response rate of 74%, significantly higher than the 42% observed with Kadcyla® plus anti-PD1 (p<0.05), demonstrating enhanced anti-tumor immunity.Read More | Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint InhibitorsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Patel Samir RashmikantDirector, 10% Owner | Option | 1,209 | $32.00 | 07/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AKTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Palo Alto Investors LP | 0 % | 42.00 K | 146.02 K |
AKTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AKTX ranks across every disease it competes in
Competitive Position is a premium feature
See how AKTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAKTX News
-AKTX
Oct 1, 2026Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
Akari Therapeutics has announced a new PCT filing that expands its intellectual property portfolio related to its novel RNA splicing disrupting payload, PH1. This filing highlights PH1's ability to modulate alternative splicing in cancer cells, potentially impacting tumor growth and survival. The company aims to leverage this unique mechanism in developing differentiated antibody drug conjugates (ADCs) for various cancers.
Read more →-AKTX
Sep 8, 2026Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
Akari Therapeutics has been invited to present its innovative PH1 ADC payload platform at five major conferences in September 2026. CEO Abizer Gaslightwala will deliver keynote presentations discussing the potential of the PH1 platform and its implications for ADC efficacy and safety. This participation highlights the growing interest in novel ADC technologies and provides opportunities for strategic partnerships and collaborations.
Read more →-AKTX
Aug 27, 2026Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Akari Therapeutics participated in the Virtual Investor "Why Now" conference, where CEO Abizer Gaslightwala presented the company's investment thesis. He emphasized the pivotal moment for Akari, highlighting the demand for differentiated antibody drug conjugates (ADCs) and the advantages of their PH1 RNA splicing payload. The company aims to initiate its First-In-Human trial for AKTX-101 by mid-2027.
Read more →-AKTX
Aug 18, 2026▲ +5%on this news
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
Akari Therapeutics has reported promising preclinical data for AKTX-101, an antibody drug conjugate targeting urothelial cancer. The findings indicate significant anti-tumor activity, particularly in models resistant to existing therapies. Akari plans to initiate Phase 1 clinical trials in mid-2027, aiming to address unmet needs in the treatment landscape.
Read more →-AKTX
Aug 13, 2026▲ +7.7%on this newsshared move
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Akari Therapeutics reported its second quarter 2026 financial results, highlighting progress on its lead candidate, AKTX-101, which is moving towards a Phase 1 clinical trial set for mid-2027. The company showcased promising preclinical data at ASCO 2026, demonstrating the potential of its PH1 payload in treating KRAS-mutated pancreatic cancer. Additionally, Akari secured $8.6 million in financing and announced a strategic collaboration with Whitehawk Therapeutics to explore dual-payload ADCs.
Read more →-AKTX
Aug 4, 2026▲ +5.8%on this news
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
Akari Therapeutics has announced a strategic collaboration with WhiteHawk Therapeutics to explore dual-payload antibody drug conjugates (ADCs) that combine their respective technologies. CEO Abizer Gaslightwala highlighted the potential of this partnership to accelerate innovation in oncology treatments. The collaboration aims to leverage Akari's PH1 spliceosome-modulating payload with WhiteHawk's TOP1 inhibitor platform, enhancing therapeutic opportunities.
Read more →-AKTX
Jul 22, 2026▲ +5.5%on this news
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
Akari Therapeutics' CEO discussed the company's strategic collaboration with Whitehawk Therapeutics during a Virtual Investor interview. This partnership aims to evaluate Akari's PH1 spliceosome modulating payload technology alongside Whitehawk's ADC platform. The collaboration highlights the industry's growing interest in differentiated ADC payloads and positions Akari to contribute significantly to future oncology treatments.
Read more →-AKTX
Jul 21, 2026▼ -12.8%on this newsshared move
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
Akari Therapeutics has announced a strategic research collaboration with Whitehawk Therapeutics to evaluate Akari's PH1 payload technology alongside Whitehawk's TOP1i payload. This collaboration aims to conduct preclinical studies to assess compatibility and synergies between the two technologies, potentially leading to broader development opportunities. Both companies will jointly review the data generated from these studies.
Read more →-AKTX
Jul 7, 2026▲ +42%on this news
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
Akari Therapeutics has appointed Dr. Patricia LoRusso to its Scientific Advisory Board, enhancing its expertise as it prepares for the Phase 1 trial of AKTX-101. Dr. LoRusso brings over 25 years of experience in oncology and drug development, which will be crucial for advancing Akari's novel ADC payload targeting RNA splicing. The company aims to start its first-in-human trial by mid-2027.
Read more →-AKTX
Jul 7, 2026▲ +42%on this news
Akari Therapeutics Appoints Former AACR President andRenowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
Akari Therapeutics has appointed Dr. Patricia LoRusso to its Scientific Advisory Board, enhancing its expertise in oncology drug development. Dr. LoRusso's extensive experience will support the advancement of Akari's lead candidate, AKTX-101, which is set to enter a Phase 1 clinical trial. The company aims to leverage its novel RNA splicing modulator payload for impactful cancer therapies.
Read more →-AKTX
Jun 29, 2026▼ -9.7%on this news
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones
Akari Therapeutics has completed its previously announced PIPE, consolidating investment closings into a single event, raising approximately $8.3 million. This funding will support the advancement of AKTX-101 towards a Phase 1 clinical trial and the development of its proprietary PH1 RNA splicing modulator ADC payload. The company aims to initiate its first-in-human trial by mid-2027.
Read more →-AKTX
Jun 4, 2026▲ +5.7%on this newsshared move
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
Akari Therapeutics' CEO, Abizer Gaslightwala, discusses the company's advancements in antibody drug conjugates (ADCs) during the 2026 ASCO Annual Meeting. He highlights the significance of novel payload technologies, particularly the PH1 spliceosome-modulating platform, in treating KRAS-driven cancers. Akari's upcoming Phase 1 trial for AKTX-101 is anticipated by mid-2027, showcasing the company's commitment to innovation in oncology.
Read more →-AKTX
May 28, 2026▲ +38.5%on this news
Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance
Akari Therapeutics announced the acceptance of its abstract at the 2026 ASCO Annual Meeting, highlighting the synergy of its lead candidate AKTX-101 with adagasrib in treating KRAS-driven cancers. CEO Abizer Gaslightwala emphasized the importance of this milestone and the potential of their novel spliceosome-modulating ADC platform. The company plans to initiate a Phase 1 clinical trial by mid-2027.
Read more →-AKTX
May 22, 2026▲ +255.4%on this news· ran to +329% by day 3shared move
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
Akari Therapeutics announced promising preclinical data for AKTX-101, an ADC with a novel RNA spliceosome modulating payload, showing synergistic effects when combined with a KRAS inhibitor in pancreatic cancer models. This data, presented at ASCO 2026, highlights the potential of AKTX-101 to enhance treatment efficacy for KRAS-driven cancers. The findings suggest that RNA splicing modulation could be a viable therapeutic strategy.
Read more →-AKTX
May 21, 2026▲ +49.9%on this news· ran to +433% by day 1shared move
Akari Therapeutics Announces $5.5 Million Private Placement Offering
Akari Therapeutics has announced a successful private placement financing round expected to raise approximately $5.5 million. The funds will be utilized to advance its lead antibody drug conjugate, AKTX-101, toward a first-in-human Phase 1 clinical trial. The offering includes unregistered American Depository Shares and warrants, with proceeds aimed at working capital and corporate purposes.
Read more →-AKTX
May 18, 2026Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase
Akari Therapeutics will present at A.G.P.'s Annual Healthcare Company Showcase on May 20, 2026. CEO Abizer Gaslightwala will discuss the company's ADC pipeline, including the lead program AKTX-101, which targets cancer cells with a novel RNA splicing modulator payload. The company aims to initiate its First-In-Human trial by mid-2027.
Read more →-AKTX
May 12, 2026▼ -40.6%on this news
Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets
Akari Therapeutics has been granted a significant European patent for its novel RNA splicing modulator payload, enhancing its global intellectual property portfolio. The patent, which covers Thailanstatin-based payloads for antibody drug conjugates (ADCs), supports the development of targeted therapies across multiple tumor types. This milestone is expected to bolster Akari's ADC pipeline, including lead candidate AKTX-101, which is set to enter clinical trials by mid-2027.
Read more →-AKTX
Apr 27, 2026Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload
Akari Therapeutics has announced the acceptance of an Australian patent for its proprietary Thailanstatin analog payload used in antibody-drug conjugates (ADCs) aimed at treating cancer. This patent broadens Akari's global intellectual property portfolio and supports the development of its ADC candidates, including AKTX-101, which is targeting TROP2. The strengthening of its IP underscores Akari's strategy to establish a competitive edge in the ADC market, which is projected to grow significantly in the coming years. The company aims to advance its lead program into human trials by late 2026 or early 2027.
Read more →-AKTX
Apr 21, 2026Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors
Akari Therapeutics announced the acceptance of its abstract for the 2026 ASCO Annual Meeting, marking its first entry into this prestigious oncology forum. The abstract discusses AKTX-101, an antibody-drug conjugate targeting KRAS-mutated tumors, and highlights its potential therapeutic synergy with a K-RAS inhibitor. The company aims to advance AKTX-101 into Phase 1 clinical trials by late 2026 or early 2027. This milestone complements Akari's focus on innovative cancer treatments leveraging novel RNA splicing modulation.
Read more →-AKTX
Apr 20, 2026Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
Akari Therapeutics announced positive preclinical data for AKTX-101, a TROP2-targeting antibody drug conjugate, at the AACR Annual Meeting 2026. This data indicates that AKTX-101 exhibits superior potency compared to existing TROP2 ADCs using Topoisomerase I inhibitors across various cancer types. The novel payload may provide an effective solution against drug resistance, potentially leading to improved patient outcomes. With the projected growth of the TROP2 ADC market, Akari is poised to advance AKTX-101 into clinical trials by early 2027.
Read more →About Akari Therapeutics Plc
Headquarters401 EAST JACKSON STREET, TAMPA, FL, 33602
Founded2004
BIOPHARMAWATCH ELITE PLUS
Trade the next AKTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime